Vinge Logotype
Svenska English 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge has advised OGI in connection with the sale of Swedsecur to Valedo Partners
Mandate

Vinge has advised OGI in connection with the sale of Swedsecur to Valedo Partners

March 28, 2018 M&A

Vinge has advised Olsson Groth Invest AB in connection with the sale of Swedsecur AB to Valedo Partners III AB through Prosero Security AB. 

Swedsecur delivers advanced security solutions and specializes in system integration of various IT, alarm, passage, monitoring and security solutions. Prosero Security consists of a number of security companies in Sweden and Norway and conducts operations relating to the installation and service of locks, alarms and monitoring solutions. Prosero Security’s total annual turnover currently amounts to approximately MSEK 550.

Vinge’s team consisted of partners Kristian Ford and Anna Edström (real estate related issues).
 

Related

Vinge advises Trianon in connection with directed share issue and tender offer for subordinated sustainable capital securities

 Vinge advises Fastighets Aktiebolaget Trianon (publ) in connection with a directed share issue of SEK 184 million and a tender offer for outstanding subordinated perpetual floating rate callable sustainable capital securities.
April 19, 2024

Vinge advises Blackstone in connection with its investment in Winthrop Technologies

 Vinge, as local Swedish counsel, advised Blackstone Tactical Opportunities and affiliated funds (“Blackstone”) in connection with a strategic partnership with Winthrop Technologies Limited (“Winthrop Technologies”).
April 17, 2024

Vinge has advised Hansa Biopharma in connection with a directed share issue of SEK 372 million

 Vinge has advised Hansa Biopharma AB (publ) in connection with a directed share issue through which the company raises proceeds of SEK 372 million before transaction costs. Hansa Biopharma is a commercial-stage biopharmaceutical company pioneering the development and commercialization of innovative, lifesaving and life altering treatments for patients with rare immunological conditions. Hansa Biopharma’s ordinary share is listed on Nasdaq Stockholm.
April 16, 2024